A multi-arm Phase 1b trial evaluating the safety and efficacy of the combination of binimetinib, avelumab and talazoparib across various tumor types

Trial Profile

A multi-arm Phase 1b trial evaluating the safety and efficacy of the combination of binimetinib, avelumab and talazoparib across various tumor types

Planning
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Avelumab (Primary) ; Binimetinib (Primary) ; Talazoparib (Primary)
  • Indications Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Dec 2017 New trial record
    • 19 Dec 2017 The study is expected to begin by the third quarter of 2018, as reported in an Array BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top